Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy

Most patients receiving highly or moderately emetogenic chemotherapy experience chemotherapy‐induced nausea and vomiting without antiemetic prophylaxis. While neurokinin‐1 receptor antagonists (NK‐1RAs) effectively prevent emesis, their ability to prevent nausea has not been established. We evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Navari, Rudolph M., Rapoport, Bernardo L., Powers, Dan, Arora, Sujata, Clark‐Snow, Rebecca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051205/
https://www.ncbi.nlm.nih.gov/pubmed/29790666
http://dx.doi.org/10.1002/cam4.1560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051205/
https://www.ncbi.nlm.nih.gov/pubmed/29790666
http://dx.doi.org/10.1002/cam4.1560

Ejemplares similares